NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NGM Biopharmaceuticals, Inc. (NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the initiation of a Phase 1a/1b clinical study of NGM120, a first-in-class antagonistic antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling, for the potential treatment of cancer and cancer anorexia/cachexia syndrome (CACS). CACS is the uncontrolled wasting of both skeletal muscle and fat that is a common co-morbidity of cancer and is associated with shortened survival in cancer patients.
The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting. The previously announced date and time of the Annual Meeting, Wednesday, May 20, 2020 at 7:30 a.m. Pacific Daylight Time, as disclosed in the previously distributed Notice of the Annual Meeting and Definitive Proxy Statement (the “Notice and Proxy Statement”), has not changed. Stockholders will not be able to attend the Annual Meeting in person.
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2020 -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for.
In her role as CFO, which will take effect on July 13, 2020, Ms. Nolan Mangini will oversee finance, business development and investor relations at NGM. “Siobhan’s deep financial expertise, coupled with her broad leadership experience spanning a myriad of critical business functions, will enable her to have a far-reaching impact across our company as she leads the refinement and implementation of strategic, operational and financial planning to position NGM for long-term growth and success.”
NGM Biopharmaceuticals, Inc. (NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced positive preliminary topline results from the 24-week double-blind, randomized, placebo-controlled cohort (Cohort 4) of an adaptive Phase 2 study evaluating the efficacy, safety and tolerability of 1 mg aldafermin in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) with stage 2 or 3 liver fibrosis (F2-F3). Aldafermin (formerly NGM282), NGM’s lead wholly-owned drug candidate, is an engineered variant of the human hormone FGF19 being developed as a once-daily treatment for patients with NASH.
Will the new coronavirus cause a recession in US in the next 6 months? On February 27th, we put the probability at 75% and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to […]
-- Initiated Phase 2b ALPINE 4 clinical study of aldafermin (formerly NGM282) in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4 fibrosis) -- --.
The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals
A WHO official calls Gilead's drug the best current chance for a drug to help people infected with the coronavirus Covid-19, sending the Foster City-based company's stock upwards.
The biotech sector was in focus with pipeline updates from a few small biotech companies.
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2020 -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, February 24, 2020 at 8:30 a.m..
The world’s population is getting older, rapidly. According to the United Nations, the fastest-growing age group across the world is adults aged 65 and older, with it predicting one out of every six people will be 65 or older by 2050. This means that the age group will make up 16% of the world’s total population, 9% higher than it was in 2011, with this figure expected to be larger in North Africa and Europe.To this end, investors are looking for ways to capitalize on the growing opportunity within the healthcare space. In order to pinpoint the most compelling opportunities capable of delivering handsome returns through 2020 and beyond, we turned to the seasoned pros from investing firm Cowen & Co.Using TipRanks.com, we were able to get the full scoop on 3 healthcare stocks that the firm’s top rated analysts are picking. If it wasn’t enough that each has received enough Street Support over the last three months to achieve a “Strong Buy” consensus rating, all of the names boast impressive upside potential. We’re talking more than 45% here.BioMarin Pharmaceutical (BMRN) BioMarin is best known for developing innovative therapies to meet the needs of patients with orphan disease, a group of diseases that affects less than 200,000 people in the U.S. The group includes cystic fibrosis, Lou Gehrig's disease, Tourette's syndrome as well as several others.Even though shares have experienced some rockiness year-to-date, 5-star Cowen analyst Phil Nadeau reminds investors that BMRN has demonstrated portfolio-wide progress. Its Naglazyme drug remains the only treatment option for the 1,000 people with MPS-VI, an inherited life-threatening disease caused by a deficiency of the enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs). According to the analyst’s forecasts, the drug could generate revenue of $470 million in 2024, up from $346 million in 2018.The biotech isn’t stopping there. During BMRN’s recent investor R&D day, the company announced that data from its extended Phase 2 trial of Vosoritide, its drug designed to treat Achondroplasia, a bone growth disorder, suggested positive results in terms of efficacy. As management pointed out that the results can most likely be replicated, it’s no wonder Nadeau is excited. “We are optimistic for success in the Phase 3 study and we think that should the Phase 2 profile be replicated, this would drive wide and rapid adoption,” he commented.With substantial steps forward for its hemophilia A treatment and its gene therapies for PKU and HAE, Nadeau concludes that BMRN is a Buy. Not to mention the analyst’s $150 price target indicates that shares could double in the next twelve months. (To watch Nadeau’s track record, click here)In general, the rest of the Street also likes what it’s seeing. 11 Buy ratings and 3 Holds assigned in the last three months amount to a ‘Strong Buy’ ranking. Additionally, the $109 average price target brings the upside potential to 40%. (See BioMarin stock analysis on TipRanks)SAGE Therapeutics (SAGE)SAGE wants to offer better treatment options for patients with neuropsychiatric disorders such as postpartum depression (PPD) and major depressive disorder (MDD). While results from its most recent quarter failed to impress, Cowen thinks that there’s plenty of room for growth here.Analyst Ritu Baral notes that during the third quarter, its Zulresso drug, which launched in Q2 with small revenues, demonstrated lackluster sales growth. The analyst believes that as sales are likely to maintain slow growth until the second half of 2020, investors should instead focus on the upcoming SAGE-217 Phase 3 readout for MDD in the fourth quarter.The results from its Phase 2 study were resoundingly positive, as they demonstrated significant levels of efficacy. This lends itself to Baral’s argument that SAGE-217 “provides significant blockbuster market potential”. “Topline data from the Ph3 MOUNTAIN trial evaluating SAGE-217 in MDD is expected to be a major catalyst for SAGE shares. Therefore, in our view, this could lead to about 30-40% upside for shares,” the Cowen analyst explained.Baral adds, “We believe SAGE has a strong CNS pipeline with several potentially value-creating shots on goal over the next few years.” Bearing this in mind, the five-star analyst reiterated the bullish call and $207 price target. This target conveys her confidence in SAGE’s ability to surge about 40% over the next twelve months. (To watch Baral’s track record, click here)Similarly, Wall Street takes a bullish approach when it comes to SAGE. With 7 Buys and 1 Hold, the consensus among analysts is that the biotech name is a ‘Strong Buy.’ Its $204 average price target implies 35% upside potential from today's closing price. (See SAGE stock analysis on TipRanks)NGM Biopharmaceuticals (NGM)Using its unique “in vivo” discovery approach to characterize relevant biological processes, NGM has been able to create novel compounds to fight diseases like non-alcoholic steatohepatitis (NASH). NASH is an inflammatory liver disease that can cause too much fat to accumulate in the liver.While the company posted a $10.9 million net loss in Q3, the outcome of its Phase 2a Cohort 4 study for lead candidate Aldafermin could drive a turnaround. Top-line data for the PBO-controlled biopsy to evaluate its ability to treat NASH are expected to be released in the first quarter of 2020.Ritu Baral, who also covers NGM, highlights the fact that “the compound has previously shown robust decreases in MRI-PDFF and demonstrated regression of fibrosis (the thickening and scarring of connective tissue) by 1 stage in 25% and 42% of patients treated with aldafermin 1mg and 3mg respectively at 12-weeks.”It also doesn’t hurt that the company’s pipeline includes candidates for oncology and ophthalmic conditions that are in earlier development, as well as its NGM313 humanized antibody in development for NASH and type 2 diabetes.All of this contributed to Baral’s decision to maintain her bullish thesis. “We believe NGM Bio’s precision biology pipeline has significant promise in multiple diseases with high unmet need,” she noted. Along with the Buy recommendation, the $25 price target puts the potential twelve-month gain at a whopping 70%.The rest of the Street appears to mirror Baral’s sentiment. With 4 Buys received in the last three months compared to no Holds or Sells, the message is clear: NGM is a ‘Strong Buy’. On top of this, shares could soar 61% in the next twelve months based on the $23.67 average price target. (See NGM stock analysis on TipRanks)
Largest insider trades of the week Continue reading...
--Successfully completed 24-week Phase 2 study (Cohort 4) of aldafermin in non-alcoholic steatohepatitis (NASH) patients, and announced topline results demonstrating positive.
NGM Biopharmaceuticals Inc (NASDAQ: NGM), which went public about a year back, has seen its shares trade mostly below the IPO price of $16. An analyst at Raymond James said the stock deserves to trade at a much higher valuation.The NGM Analyst Steven Seedhouse initiated coverage of NGM shares with a Strong Buy and $31 price target. The NGM Thesis NGM has created a "sizable novel biologic pipeline," and among its pipeline candidates, aldafermin, MK-3655 and NGM621 drive Raymond James' thesis and model, Seedhouse said in a Monday initiation note. (See his track record here.)Aldafermin, which is being evaluated in non-alcoholic steatohepatitis, or NASH, with fibrosis, seems comparable to Intercept Pharmaceuticals Inc's (NASDAQ: ICPT) Ocaliva -- the frontrunner in the NASH race -- on fibrosis, but with better NASH resolution and no pruritus in a Phase 2b study, the analyst said.See Also: Teva Analyst Says Shares Are Pricing In Too Much Risk "Aldafermin may ultimately become the first therapy to achieve both FDA-recommended co-primary endpoints in NASH," he said. Seedhouse said he expects the outcome of Ocaliva's June 9 AdCom to provide key insight into the potential downstream approvability/label for aldafermin in NASH.The analyst is also bullish about MK-3655, which is a potent insulin sensitizer targeting Type 2 diabetes patients with NASH."Given positive results on T2DM biomarkers and liver fat reduction in Phase 1b, MK-2655 looks like a promising candidate for F0/F1 NASH with diabetes," he said. NGM Price Action NGM shares were trading 4.63% higher at $14.02 at the time of publication Tuesday.Latest Ratings for NGM DateFirmActionFromTo Apr 2020Raymond JamesInitiates Coverage OnStrong Buy Mar 2020CitigroupMaintainsBuy Mar 2020StifelMaintainsBuy View More Analyst Ratings for NGM View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes .6B Opioid Settlement * NGM Biopharma Shares Spike Higher On Positive NASH Study Results(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
NGM Biopharmaceuticals, Inc. (NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the expansion of its Board of Directors with the appointment of Shelly Guyer, who currently serves as Chief Financial Officer (CFO) of Invitae Corporation (NVTA). “We are thrilled to welcome Shelly to our Board of Directors,” said David J. Woodhouse, Ph.D., Chief Executive Officer of NGM Bio.
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.45% and 22.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]
NGM Biopharmaceuticals, Inc. (NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that, effective March 13, 2020, Aetna Wun Trombley, Ph.D. will step down as President and Chief Operating Officer (COO) of the company to assume the role of Chief Executive Officer at an undisclosed privately held company. Dr. Trombley will continue with NGM on a consulting basis for an interim period to help on strategic topics and to provide operational continuity during the transition process. “On behalf of the NGM team, I want thank Aetna for her nine years of dedication and tremendous contributions,” said David J. Woodhouse, Ph.D., NGM’s Chief Executive Officer.